Total submissions: 20
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000111772 | SCV000578000 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-06-29 | reviewed by expert panel | curation | Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; http://priors.hci.utah.edu/PRIORS/) and frequency 0.0052 (African), derived from ExAC (2014-12-17). |
Labcorp Genetics |
RCV000047711 | SCV000075724 | benign | Hereditary breast ovarian cancer syndrome | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000173831 | SCV000167250 | benign | not specified | 2013-11-04 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV000162519 | SCV000212913 | likely benign | Hereditary cancer-predisposing syndrome | 2014-07-23 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Counsyl | RCV000111772 | SCV000220557 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-07-30 | criteria provided, single submitter | literature only | |
Eurofins Ntd Llc |
RCV000173831 | SCV000224987 | benign | not specified | 2014-10-07 | criteria provided, single submitter | clinical testing | |
Michigan Medical Genetics Laboratories, |
RCV000111772 | SCV000267697 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-04-21 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000476210 | SCV000540965 | benign | Familial cancer of breast | 2017-02-23 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001796720 | SCV000602729 | benign | not provided | 2021-09-08 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162519 | SCV000683012 | benign | Hereditary cancer-predisposing syndrome | 2015-10-09 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000047711 | SCV002025990 | benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000173831 | SCV002066484 | benign | not specified | 2019-07-14 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000162519 | SCV002538092 | benign | Hereditary cancer-predisposing syndrome | 2020-04-28 | criteria provided, single submitter | curation | |
CHEO Genetics Diagnostic Laboratory, |
RCV000735514 | SCV003838904 | likely benign | Breast and/or ovarian cancer | 2023-01-18 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV000173831 | SCV004026792 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000111772 | SCV000144304 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000173831 | SCV000591370 | benign | not specified | no assertion criteria provided | clinical testing | The p.Thr703Thr variant is not expected to have clinical significance because it does not alter an amino acid residue, is not located near a splice junction, and is also listed in the dbSNP database as coming from a "clinical source" (rs4986844) with a MAF score of 0.001. And it was identified in varying frequencies in various ethnic groups from the HapMap project. It was also reported in 20/111260 proband chromosomes of individuals from HBOC families, and classified as a polymorphism in the study by Myriad; although no control chromosomes were tested to establish the variant’s frequency in the general population (Judkins_2005). In addition, the variant was also identified in the UMD (x4), BIC (x2), Exome Server and BOCs databases. In summary, based on the above information, the variant is classified as predicted benign. | |
Foulkes Cancer Genetics LDI, |
RCV000735514 | SCV000863652 | benign | Breast and/or ovarian cancer | 2012-08-27 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000173831 | SCV002036046 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001796720 | SCV002038271 | likely benign | not provided | no assertion criteria provided | clinical testing |